BloodPressureHeartMeds.Net

PGT, Quintiles collaborate to bring genomic testing into mainstream drug development

March 17, 2017

PGT Chief Commercial Officer Frank Massam, Ph.D., said: "Our first project with Quintiles is a renal cancer clinical trial to identify genetic markers predictive of both adverse events and efficacy, but our workflows are appropriate to all therapeutic areas. We are currently running programs in breast cancer, leukemia and Alzheimer's disease. We are proud to be associated with the work that Quintiles is leading to deliver real patient benefits from cutting-edge genomic research."

Both companies will seek other opportunities to demonstrate to biopharma companies, payers, academic researchers and patient groups the value of this approach to improving human health.

This collaboration further enhances Quintiles' established capabilities in genomics- and biomarker- based discovery and research. In addition to general genomic analyses provided by Quintiles Global Central Laboratories, Quintiles' Translational R&D Oncology group offers innovative genomic technologies to drive novel biomarker discovery and support more intelligent, data-driven clinical trial design and implementation for its customers.

Source: Quintiles